An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. [electronic resource]
Producer: 20021125Description: 1117-24 p. digitalISSN:- 0269-2813
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Chronic Disease
- Crohn Disease -- complications
- Drug Resistance
- Female
- Fistula -- drug therapy
- Gastrointestinal Agents -- administration & dosage
- Humans
- Immunosuppressive Agents -- administration & dosage
- Infliximab
- Male
- Severity of Illness Index
- Thalidomide -- administration & dosage
- Treatment Outcome
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.